Rachel Eguia

Rachel Eguia is a Senior Associate Scientist at Variant Bio since March 2023, previously serving as an Associate Scientist at Century Therapeutics, Inc. from August 2022 to January 2023. At Century Therapeutics, Eguia led lentivirus and gammaretrovirus production, optimizing a qRT-PCR-based lentiviral titering assay for quality control. Prior experience includes serving as a Research Technician III at Fred Hutch, where Eguia studied viral evolution, and as a Research Technician II, collaborating on deep mutational scanning of influenza. Eguia’s early career includes a Postbaccalaureate Research Education Program Fellowship at the University of Washington, focusing on CRISPR/Cas9 and innate restriction factors against influenza, and as a Research Technician at Johnson Research LLC, assisting in clinical trials. Eguia holds a Bachelor of Arts in Biochemistry, Biophysics, and Molecular Biology from Whitman College.